To establish TGF-β mRNA-IAJD34 as a therapeutic in this ALI model, we will need to characterize the effect of TGF-b at 7 days or longer post-injury, which may require multiple dosing regimens. Here, TGFB1 is linked to acute respiratory distress syndrome.